On November 16, Elevance Health rose 3.42% in Regular Trading, trading at $444.08 per share, with turnover of $58.62 million.
The clearest recent catalyst in the news flow was the company’s reaffirmation of full-year adjusted EPS of at least $29 and benefit expense ratio guidance of 90.2% plus or minus 50 basis points, alongside Cantor Fitzgerald’s price-target increase to $493 from $450.
That backdrop followed stronger third-quarter results reported on October 21, when Elevance Health posted adjusted EPS of $6.99 on revenue of $50.44 billion, both above consensus, and raised its full-year adjusted EPS outlook to at least $29. Recent coverage also noted that while investors remain attentive to Medicaid utilization pressure and expected exits from some state Medicaid markets, the reaffirmed guidance and latest target-price increase reinforced expectations for earnings resilience.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments